Thus, the effectiveness of BS in reducing fat mass and resolving obesity-related comorbidities (such as T2D, HBP, or fatty liver) could lead to changes in both circulating GDF15 and its primary tissue source. The gene discussed is GDF15; the disease is obesity disorder.